PMID- 32982230
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20220417
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 15
DP  - 2020
TI  - Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles 
      Loaded with Docetaxel.
PG  - 6737-6748
LID - 10.2147/IJN.S267177 [doi]
AB  - PURPOSE: Chemotherapy of colon cancer needs improvement to mitigate the severe 
      adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study 
      is to develop a novel targeted drug delivery system (TDDS) with practical 
      application potential for colon cancer treatment. METHODS: The TDDS was built by 
      loading docetaxel (DTX) in albumin nanoparticles (NPs) that were functionalized 
      with nucleolin-targeted aptamers (AS1411). RESULTS: The TDDS (Apt-NPs-DTX) had an 
      average size of 62 nm and was negatively charged with a zeta potential of -31.2 
      mV. DTX was released from the albumin NP with a typical sustained release 
      profile. Aptamer-guided NPs were preferentially ingested by nucleolin-expressing 
      CT26 colon cancer cells vs the control cells. In vitro cytotoxicity study showed 
      that Apt-NPs-DTX significantly enhanced the killing of CT26 colon cancer cells. 
      Importantly, compared with non-targeted drug delivery, Apt-NPs-DTX treatment 
      significantly improved antitumor efficacy and prolonged the survival of 
      CT26-bearing mice, without raising systemic toxicity. CONCLUSION: The results 
      suggest that Apt-NPs-DTX has potential in the targeted treatment of colon cancer.
CI  - (c) 2020 Yu et al.
FAU - Yu, Zhen
AU  - Yu Z
AUID- ORCID: 0000-0001-6200-0944
AD  - Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing, People's Republic of China.
FAU - Li, Xundou
AU  - Li X
AD  - Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing, People's Republic of China.
FAU - Duan, Jinhong
AU  - Duan J
AD  - Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing, People's Republic of China.
FAU - Yang, Xian-Da
AU  - Yang XD
AD  - Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200911
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (AGRO 100)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Aptamers, Nucleotide)
RN  - 0 (Drug Carriers)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 15H5577CQD (Docetaxel)
RN  - 27432CM55Q (Serum Albumin, Bovine)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacokinetics
MH  - Aptamers, Nucleotide
MH  - CHO Cells
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*drug therapy/pathology
MH  - Cricetulus
MH  - Docetaxel/*administration & dosage/pharmacokinetics
MH  - Drug Carriers/administration & dosage/chemistry
MH  - Drug Delivery Systems/*methods
MH  - Drug Liberation
MH  - Female
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*administration & dosage/chemistry
MH  - Neoplasms, Experimental/drug therapy/pathology
MH  - Oligodeoxyribonucleotides/*administration & dosage/chemistry
MH  - Serum Albumin, Bovine/chemistry
PMC - PMC7494387
OTO - NOTNLM
OT  - aptamer
OT  - colon cancer
OT  - nanoparticles
OT  - targeted drug delivery system
COIS- The authors declare no competing interests.
EDAT- 2020/09/29 06:00
MHDA- 2020/11/18 06:00
PMCR- 2020/09/11
CRDT- 2020/09/28 05:37
PHST- 2020/06/10 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/09/11 00:00 [pmc-release]
AID - 267177 [pii]
AID - 10.2147/IJN.S267177 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2020 Sep 11;15:6737-6748. doi: 10.2147/IJN.S267177. 
      eCollection 2020.